CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 791 - 800 of 842
Study Number Lead Group Study Title CIRB Study Status
S1701 SWOG A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Adult CIRB - Late Phase Emphasis Available to Open
S0427 SWOG A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin; with and without Docetaxel; Cisplatin; and 5-FluorouracilInduction Chemotherapy; in Patients with Advanced Oropharyngeal Squamous Cell Cancer Adult CIRB - Late Phase Emphasis Completed
SWOG-9007 SWOG Cytogenetic Studies in Leukemia Patients Adult CIRB - Late Phase Emphasis Completed
S1400 SWOG A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) Adult CIRB - Late Phase Emphasis Available to Open
S1905 SWOG A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) Adult CIRB - Late Phase Emphasis Available to Open
S1605 SWOG Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1207 SWOG Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy Adult CIRB - Late Phase Emphasis Available to Open
S0307 SWOG Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1607 SWOG A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy Adult CIRB - Late Phase Emphasis Available to Open
S1500 SWOG A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) Adult CIRB - Late Phase Emphasis Available to Open
Displaying 791 - 800 of 842